Cancer Investigation最新文献_第6页

Current Landscape of Anti-HER2 Targeted Therapy in Breast Cancer: Challenges and Future Perspectives. 乳腺癌抗her2靶向治疗的现状：挑战和未来展望

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-08-01 Epub Date: 2026-05-18 DOI: 10.1080/07357907.2026.2672753

Pooja Bharali, Vikrant Mehta, Subhash Chand, Harish Chander

引用次数: 0

Circulating Tumor DNA in Tracking Minimal Residual Disease and Recurrence in Ovarian Cancer: A Retrospective Cohort. 循环肿瘤DNA在追踪卵巢癌微小残留疾病和复发中的作用：一项回顾性队列研究。

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-08-01 Epub Date: 2026-05-22 DOI: 10.1080/07357907.2026.2675657

Fei Meng, Qingyang Liu, Chenchen Cheng, Yanting Sun, Yuange He, Yanyu Li, Jinhua Zhou, Juan Wang, Hongmei Ding, Youguo Chen, Fangrong Shen

{"title":"Circulating Tumor DNA in Tracking Minimal Residual Disease and Recurrence in Ovarian Cancer: A Retrospective Cohort.","authors":"Fei Meng, Qingyang Liu, Chenchen Cheng, Yanting Sun, Yuange He, Yanyu Li, Jinhua Zhou, Juan Wang, Hongmei Ding, Youguo Chen, Fangrong Shen","doi":"10.1080/07357907.2026.2675657","DOIUrl":"10.1080/07357907.2026.2675657","url":null,"abstract":"Purpose: After radical treatment for ovarian cancer, the presence of minimal residual disease (MRD) remains a major obstacle to achieving cure. We explored the prognostic and translational value of MRD assessment by tracking circulating tumor DNA (ctDNA) in blood using the tumor-free approach.Methods: We retrospectively enrolled 34 ovarian cancer patients who underwent surgical treatment at our hospital, all with available postoperative and serial blood samples. ctDNA-based MRD status was analyzed to evaluate its association with recurrence risk and disease-free survival (DFS).Results: In our study, the longitudinal monitoring of ctDNA showed satisfactory performance, with the sensitivity and specificity were 85% and 92.9%, respectively. 47.06%(16/34) patients had ctDNA-negative status. Patients with ctDNA positive in longitudinal monitoring have significantly worse prognosis and shorter DFS compared to those with ctDNA negative (p < 0.0001, DFS: unreached vs. 14.55 months; HR = 0.11; 95% CI, 0.05 to 0.27). A tumor-informed approach was compared with a tumor-free approach, revealing that when referring to the primary tumor mutation, 30.4% of originally positive samples were corrected to negative during MRD monitoring.Conclusion: ctDNA holds potential in predicting recurrence risk in ovarian cancer patients, particularly through longitudinal monitoring.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"769-781"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Studying the Relations of Behavioral Inhibition and Activation System Sensitivities and Time Perspective Orientations with Skin Cancer Screening Behaviors in Older Adults: Do Skin Cancer Screening Perceptions Mediate These Relations? 研究老年人皮肤癌筛查行为与行为抑制、激活系统敏感性和时间视角取向的关系：皮肤癌筛查认知是否介导了这些关系？

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-08-01 Epub Date: 2026-05-31 DOI: 10.1080/07357907.2026.2675658

Matt C Howard

引用次数: 0

Practice-Changing Trials in Gastrointestinal Cancers at ASCO 2025: A Critical Review and Clinical Context. ASCO 2025胃肠癌实践改变试验：关键回顾和临床背景。

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-07-01 Epub Date: 2026-04-10 DOI: 10.1080/07357907.2026.2654136

Nabil Ismaili

{"title":"Practice-Changing Trials in Gastrointestinal Cancers at ASCO 2025: A Critical Review and Clinical Context.","authors":"Nabil Ismaili","doi":"10.1080/07357907.2026.2654136","DOIUrl":"10.1080/07357907.2026.2654136","url":null,"abstract":"The ASCO 2025 meeting featured several phase III trials with the potential to impact gastrointestinal cancer management. CheckMate 577 reported mature overall survival (OS) data for adjuvant nivolumab in esophageal/GEJ cancer; however, OS benefit was not statistically significant in the intent-to-treat population and appeared restricted to PD-L1-positive tumors. MATTERHORN demonstrated significant improvements in event-free survival and OS with perioperative durvalumab plus FLOT in gastric/GEJ cancer. In stage III dMMR colon cancer, ATOMIC supported adjuvant atezolizumab plus chemotherapy, though questions persist about chemotherapy necessity and neoadjuvant immunotherapy. For advanced disease, BREAKWATER established encorafenib-based triplet therapy as first-line standard for BRAF V600E-mutant metastatic colorectal cancer, while DESTINY-Gastric04 confirmed trastuzumab deruxtecan as superior second-line therapy for HER2-positive gastric cancer, mandating re-biopsy. Given the great interest in circulating tumor DNA, we integrate the ESMO 2025 DYNAMIC-III trial, demonstrating ctDNA-guided de-escalation reduces toxicity with outcomes approaching standard care. These advances mandate comprehensive biomarker testing while highlighting persistent evidence gaps.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"700-706"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment Strategies for Biliary Tract Cancer: A Surgical Perspective from Historical Evolution to Neoadjuvant Therapy. 胆道癌的治疗策略：从历史演变到新辅助治疗的外科视角。

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-07-01 Epub Date: 2026-05-13 DOI: 10.1080/07357907.2026.2670355

Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru, Sunao Uemura, Shuta Tamura

引用次数: 0

Roles of Metastasis Associated Fibroblasts in Paclitaxel Resistance of Brain Metastatic Tumor Cells: Evaluation in Metastatic Organoids. 转移相关成纤维细胞在脑转移肿瘤细胞紫杉醇耐药中的作用：转移类器官的评估。

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-07-01 Epub Date: 2026-06-17 DOI: 10.1080/07357907.2025.2596852

Mahnaz Siahi, Mohammad Kamalabadi-Farahani, Amir Atashi

{"title":"Roles of Metastasis Associated Fibroblasts in Paclitaxel Resistance of Brain Metastatic Tumor Cells: Evaluation in Metastatic Organoids.","authors":"Mahnaz Siahi, Mohammad Kamalabadi-Farahani, Amir Atashi","doi":"10.1080/07357907.2025.2596852","DOIUrl":"10.1080/07357907.2025.2596852","url":null,"abstract":"Background: Some breast cancer patients experience the devastating effects of brain metastases. The metastasis-associated fibroblasts (MAFs), the most abundant cells in the metastatic microenvironment, have an important role in chemoresistance. The MAFs' roles in paclitaxel resistance of brain metastatic tumor cells were evaluated in metastatic organoids.Methods: Brain metastatic cells, known as 4T1B, were isolated and expanded from the brains of cancerous mice. Alginate-based metastatic organoids were prepared from the culture of 4T1B and 3T3 fibroblasts in an alginate solution. Cytotoxic activity of paclitaxel against 4T1B in 3D (3-Dimensional) culture was evaluated by MTT. For molecular analysis, real-time PCR was done.Results: Our results proved that in brain metastatic organoids, fibroblasts cause a significant increase in paclitaxel resistance. Molecular analysis showed that the expression level of α-smooth muscle actin (α-SMA) increased in MAF compared to normal fibroblasts. Surprisingly, the expression level of fibroblast-specific protein 1 (FSP-1) decreased compared to normal fibroblasts.Conclusion: Here, we reveal the pivotal roles of MAFs in chemoresistance and discuss their molecular properties. Our approach involves exploring various therapeutic techniques to comprehend MAFs and presenting therapeutic perspectives for metastatic cancer treatment.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"559-566"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CTL-NK Signature Based on Immune Gene Profiling and IHC Predicts Clinical Outcomes in Triple-Negative Breast Cancer. 基于免疫基因谱和免疫组化的CTL-NK标记预测三阴性乳腺癌的临床结局。

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-07-01 Epub Date: 2026-03-25 DOI: 10.1080/07357907.2026.2644899

Ahmed J Alfahdawi, Ali Mohammed Sameen, Ashjan Mohammed Hussien, Noor T Al-Bayatee, Tareq Hafdi Abdtawfeeq, Rashied M Rashied, Maysam N Ahmed, Majid S Jabir

{"title":"CTL-NK Signature Based on Immune Gene Profiling and IHC Predicts Clinical Outcomes in Triple-Negative Breast Cancer.","authors":"Ahmed J Alfahdawi, Ali Mohammed Sameen, Ashjan Mohammed Hussien, Noor T Al-Bayatee, Tareq Hafdi Abdtawfeeq, Rashied M Rashied, Maysam N Ahmed, Majid S Jabir","doi":"10.1080/07357907.2026.2644899","DOIUrl":"10.1080/07357907.2026.2644899","url":null,"abstract":"Aim: Triple-negative breast cancer (TNBC) lacks targeted therapies and demonstrates heterogeneous outcomes. Tumor-infiltrating lymphocytes (TILs) are candidate prognostic biomarkers that reflect the tumor immune microenvironment. This study evaluated the prognostic value of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, with emphasis on granulysin (GNLY) and granzyme B (GZMB), in TNBC.Materials & methods: We combined NanoString immune gene profiling with whole-slide immunohistochemistry (IHC) in a TNBC cohort (n = 155). Quantitative and spatial analyses were performed to assess CTL and NK cell infiltration and their associations with clinicopathological features and survival outcomes.Results: High TIL density (≥10%) and elevated CTL-NK scores (≥2) correlated with lower tumor stage, absence of lymphovascular invasion (LVI), and favorable immune subset ratios (all p < 0.05). In multivariable analysis, absence of LVI, high CD4+ and CD8+ infiltration, and CTL-NK score ≥2 independently predicted improved disease-free survival (DFS; hazard ratio [HR] range 0.45-0.62, all p < 0.05). CD4+ infiltration demonstrated the strongest prognostic effect, while CD8+ infiltration and the CTL-NK score also conferred independent benefit.Conclusion: Quantitative and spatial assessment of CTL and NK infiltration provides independent prognostic information in TNBC. The CTL-NK score can be integrated into routine pathology and may refine risk stratification, supporting personalized immunotherapy strategies.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"567-584"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mutational and Expressional Deregulation of the CHEK1 Gene in Breast Cancer Patients. 乳腺癌患者CHEK1基因的突变和表达失调。

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-07-01 Epub Date: 2026-05-29 DOI: 10.1080/07357907.2026.2661618

Azhar Mehmood, Ishrat Mahjabeen, Asif Nisar, Muhammad Umar, Mahmood Akhtar Kayani

{"title":"Mutational and Expressional Deregulation of the CHEK1 Gene in Breast Cancer Patients.","authors":"Azhar Mehmood, Ishrat Mahjabeen, Asif Nisar, Muhammad Umar, Mahmood Akhtar Kayani","doi":"10.1080/07357907.2026.2661618","DOIUrl":"10.1080/07357907.2026.2661618","url":null,"abstract":"Background: Breast cancer burden is increasing day by day. The identification of novel genetic markers based on polymorphism and expression analysis is necessary to reduce the suffering of patients.Aims: The current study is divided into two parts; firstly, the possible association of hotspot CHEK1 gene single nucleotide polymorphisms (SNPs) was investigated in breast cancer patients. Secondly, the relative expression of CHEK1 gene was assessed at the mRNA level.Methods: For SNP analysis 500 breast cancer patients and 500 controls were used. Tetra Amplification-Refractory Mutation System (ARMS) PCR was used for screening of the selected polymorphisms. Expression profiling of the CHEK1 gene was assessed in 200 breast tumors along with their adjacent uninvolved healthy tissue using quantitative real time (RT) PCR.Results: Data analysis showed that mutant genotype of selected SNPs (rs521102, p < 0.002; rs284722, p < 0.001 and rs35817404, p < 0.0001) of the CHEK1 gene showed significant association with increased tumorigenesis risk among patients compared to healthy controls. The relative expression analysis of the selected gene showed significant downregulation of the CHEK1 gene (p < 0.0001) in breast tumor tissues as compared to adjacent control tissues.Conclusion: Based on the current findings we can conclude that genetic/expression deregulation of the CHEK1 gene play an important role in increased breast cancer risk. The CHEK1 gene also plays an important role in chemotherapy resistance response among the Pakistani population.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"608-624"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differential Toxicity of Immune Checkpoint Inhibitors in Older Adults: A Large-Scale, Propensity Score-Matched Real-World Analysis. 免疫检查点抑制剂在老年人中的差异毒性：一项大规模、倾向评分匹配的现实世界分析。

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-07-01 Epub Date: 2026-04-16 DOI: 10.1080/07357907.2026.2654124

Muhammad Awidi, Muntaser Al Zyoud, Noor S Bader, Ahmad Al-Alwan, Muhammad Junaid Tariq

{"title":"Differential Toxicity of Immune Checkpoint Inhibitors in Older Adults: A Large-Scale, Propensity Score-Matched Real-World Analysis.","authors":"Muhammad Awidi, Muntaser Al Zyoud, Noor S Bader, Ahmad Al-Alwan, Muhammad Junaid Tariq","doi":"10.1080/07357907.2026.2654124","DOIUrl":"10.1080/07357907.2026.2654124","url":null,"abstract":"Background: The risk-benefit profile of immune checkpoint inhibitors (ICIs) in the understudied elderly population (≥75 years) remains poorly defined. We characterized clinical outcomes and immune-related adverse events (irAEs) in this population using a large real-world dataset.Methods: Using the TriNetX network, we identified cancer patients initiating ICIs, creating two cohorts: ≥75 and 18-74 years. After 1:1 propensity score matching (PSM), we compared overall survival, all-cause hospitalization, and 5-year irAE risk.Results: We matched 37,417 older patients to 37,417 younger controls. Older adults had worse overall survival (median 753 vs 955 days; HR 1.15; 95% CI 1.13 - 1.18). Paradoxically, they had lower risks for endocrine (RR 0.86; 95% CI 0.83 - 0.89) and gastrointestinal (RR 0.80; 95% CI 0.76 - 0.84) events. However, risks significantly increased for myocarditis (RR 1.27; 95% CI 1.05 - 1.53), myasthenia gravis (RR 2.38; 95% CI 1.76 - 3.21), polymyalgia rheumatica (RR 2.12; 95% CI 1.62 - 2.76), pemphigoid (RR 2.05; 95% CI 1.58 - 2.67), and acute kidney injury (RR 1.09; 95% CI 1.05 - 1.13).Conclusion: Patients ≥75 years exhibited poorer survival and a unique irAE profile characterized by lower overall incidence but heightened risk of specific, highly morbid toxicities. These findings highlights the need for age-specific vigilance in geriatric oncology.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"596-607"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers for Prognosis in Osteosarcoma: From Molecular Signatures to Clinical Applications. 骨肉瘤预后的生物标志物：从分子特征到临床应用。

IF 2.2 4区医学

Cancer Investigation Pub Date : 2026-07-01 Epub Date: 2026-05-13 DOI: 10.1080/07357907.2026.2671993

Elias Abboud, Guy Awad, Marc Boutros, Karim Masrouha

引用次数: 0